viscous/swallowed budesonide
PreclinicalSmall molecule
viscous/swallowed budesonide is one of 43 small molecule programs targeting Eosinophilic Esophagitis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
66 competitors in Eosinophilic Esophagitis
#DrugCompanyPhaseTrials
1Pulmicort
SSalix
Approved
Flovent
GSKApproved
Cinqair
TevaPhase 3
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Tezspire
AstraZenecaPhase 3
Fasenra
AstraZenecaPhase 3
Cromolyn Sodium
UUniversity of California, San Francisco
Approved
Xolair
RochePhase 2
Velsipity
PfizerPhase 2
Asmanex
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details